



Public Health
England















































































National Cancer Intelligence Network

Head & Neck Service profiles

October 30th 2014

- Rationale
- Structure

A PERIODIC TABLE OF VISUALIZATION METHODS

<div><div></div><div>C</div><div>continuum</div></div>	<div><div></div><div>Data Visualization Visual representations of quantitative data in schematic form (either with or without axes)</div></div> <div><div></div><div>Strategy Visualization The systematic use of complementary visual representations in the analysis, development, formulation, communication, and implementation of strategies in organizations.</div></div>										<div><div></div><div>G</div><div>graphic facilitation</div></div>						
<div><div></div><div>Tb</div><div>table</div></div>	<div><div></div><div>Ca</div><div>cartesian coordinates</div></div>	<div><div></div><div>Information Visualization The use of interactive visual representations of data to amplify cognition. This means that the data is transformed into an image, it is mapped to screen space. The image can be changed by users as they proceed working with it</div></div> <div><div></div><div>Metaphor Visualization Visual Metaphors position information graphically to organize and structure information. They also convey an insight about the represented information through the key characteristics of the metaphor that is employed</div></div>										<div><div></div><div>Me</div><div>meeting trace</div></div>	<div><div></div><div>Mm</div><div>metro map</div></div>	<div><div></div><div>Tm</div><div>temple</div></div>	<div><div></div><div>St</div><div>story template</div></div>	<div><div></div><div>Tr</div><div>tree</div></div>	<div><div></div><div>Ct</div><div>cartoon</div></div>
<div><div></div><div>Pi</div><div>pie chart</div></div>	<div><div></div><div>L</div><div>line chart</div></div>	<div><div></div><div>Concept Visualization Methods to elaborate (mostly) qualitative concepts, ideas, plans, and analyses.</div></div> <div><div></div><div>Compound Visualization The complementary use of different graphic representation formats in one single schema or frame</div></div>										<div><div></div><div>Co</div><div>communication diagram</div></div>	<div><div></div><div>Fp</div><div>flight plan</div></div>	<div><div></div><div>Cs</div><div>concept skeleton</div></div>	<div><div></div><div>Br</div><div>bridge</div></div>	<div><div></div><div>Fu</div><div>funnel</div></div>	<div><div></div><div>Ri</div><div>rich picture</div></div>
<div><div></div><div>B</div><div>bar chart</div></div>	<div><div></div><div>Ac</div><div>area chart</div></div>	<div><div></div><div>R</div><div>radar chart cobweb</div></div>	<div><div></div><div>Pa</div><div>parallel coordinates</div></div>	<div><div></div><div>Hy</div><div>hyperbolic tree</div></div>	<div><div></div><div>Cy</div><div>cycle diagram</div></div>	<div><div></div><div>T</div><div>timeline</div></div>	<div><div></div><div>Ve</div><div>venn diagram</div></div>	<div><div></div><div>Mi</div><div>mindmap</div></div>	<div><div></div><div>Sq</div><div>square of oppositions</div></div>	<div><div></div><div>Cc</div><div>concentric circles</div></div>	<div><div></div><div>Ar</div><div>argument slide</div></div>	<div><div></div><div>Sw</div><div>swim lane diagram</div></div>	<div><div></div><div>Gc</div><div>gant chart</div></div>	<div><div></div><div>Pm</div><div>perspectives diagram</div></div>	<div><div></div><div>D</div><div>dilemma diagram</div></div>	<div><div></div><div>Pr</div><div>parameter ruler</div></div>	<div><div></div><div>Kn</div><div>knowledge map</div></div>
<div><div></div><div>Hi</div><div>histogram</div></div>	<div><div></div><div>Sc</div><div>scatterplot</div></div>	<div><div></div><div>Sa</div><div>sankey diagram</div></div>	<div><div></div><div>In</div><div>information lense</div></div>	<div><div></div><div>E</div><div>entity relationship diagram</div></div>	<div><div></div><div>Pt</div><div>petri net</div></div>	<div><div></div><div>Fl</div><div>flow chart</div></div>	<div><div></div><div>Cl</div><div>clustering</div></div>	<div><div></div><div>Lc</div><div>layer chart</div></div>	<div><div></div><div>Py</div><div>minto pyramid technique</div></div>	<div><div></div><div>Ce</div><div>cause-effect chains</div></div>	<div><div></div><div>Tl</div><div>toulmin map</div></div>	<div><div></div><div>Dt</div><div>decision tree</div></div>	<div><div></div><div>Cp</div><div>cpm critical path method</div></div>	<div><div></div><div>Cf</div><div>concept fan</div></div>	<div><div></div><div>Co</div><div>concept map</div></div>	<div><div></div><div>Ic</div><div>iceberg</div></div>	<div><div></div><div>Lm</div><div>learning map</div></div>
<div><div></div><div>Tk</div><div>tukey box plot</div></div>	<div><div></div><div>Sp</div><div>spectrogram</div></div>	<div><div></div><div>Da</div><div>data map</div></div>	<div><div></div><div>Tp</div><div>treemap</div></div>	<div><div></div><div>Cn</div><div>cone tree</div></div>	<div><div></div><div>Sy</div><div>system dyn./ simulation</div></div>	<div><div></div><div>Df</div><div>data flow diagram</div></div>	<div><div></div><div>Se</div><div>semantic network</div></div>	<div><div></div><div>So</div><div>soft system modeling</div></div>	<div><div></div><div>Sn</div><div>synergy map</div></div>	<div><div></div><div>Fo</div><div>force field diagram</div></div>	<div><div></div><div>Ib</div><div>ibis argumentation map</div></div>	<div><div></div><div>Pr</div><div>process event chains</div></div>	<div><div></div><div>Pe</div><div>pert chart</div></div>	<div><div></div><div>Ev</div><div>evocative knowledge map</div></div>	<div><div></div><div>V</div><div>Yee diagram</div></div>	<div><div></div><div>Hh</div><div>heaven 'n' hell chart</div></div>	<div><div></div><div>I</div><div>infomural</div></div>

Cy

Process Visualization

Hy

Structure Visualization




Overview
Detail































Detail AND Overview

< >

Divergent thinking

> <

Convergent thinking


 Su supply demand curve	 Pc performance charting	 St strategy map	 Oc organisation chart	 Ho house of quality	 Fd feedback diagram	 Ft failure tree	 Mq magic quadrant	 Ld life-cycle diagram	 Po porter's five forces	 S s-cycle	 Sm stakeholder map	 Is ishikawa diagram	 Tc technology roadmap
 Ed edgeworth box	 Pf portfolio diagram	 Sg strategic game board	 Mz mintzberg's organigraph	 Z zwicky's morphological box	 Ad affinity diagram	 De decision discovery diagram	 Bm bcg matrix	 Stc strategy canvas	 Vc value chain	 Hy hype-cycle	 Sr stakeholder rating map	 Ta taps	 Sd spray diagram

Note: Depending on your location and connection speed it can take some time to load a pop-up picture.

© Ralph Lengler & Martin J. Eppler; www.visual-literacy.org


version 1.5

For example...



Statistic
al
process
control

Lung Cancer Mortality in Under 75s, 2004-06




Source: Compendium of Clinical and Health Indicators, 1
Note: Population is adjusted due to Standardisation Calc

Funnel
plots

				updated	Year	East of England	Bedfordshire	Cambridgeshire	East & North Hertfordshire	Great Yarmouth & Luton	Mid Essex	North Essex	North East Essex	North Essex	South East Essex	South West Essex	Suffolk	West Essex	West Hertfordshire

Tartan
rugs



Interacti
ve

Profiles... why?

Section	#	Indicator	No. of patients/ cases or value	Percentage or rate			Trust rate or percentage compared to England			Source	Period		
				Trust	Lower 95% confidence limit	Upper 95% confidence limit	England	Low- est	Range			High- est	
Size	1	Number of newly diagnosed lung cancer patients per year, 2010 [experimental] (1)	304				207	41		588	NCDR	2010	
	2	Number of NLCA patients - lung cancer	329				191	1		585	NLCA	2011	
	3	Number of NLCA patients - mesothelioma	11				10	0		31	NLCA	2011	
Demographics (based on newly diagnosed patients, 2010)	4	Patients (from #1) aged 70+	188	62%	56%	67%	61%	39%		75%	NCDR	2010	
	5	Patients (from #1) with recorded ethnicity	295	97%	94%	98%	93%	66%		100%	NCDR	2010	
	6	Patients (from #5) with recorded ethnicity which is not White-British	3	1%	0%	3%	7%	0%		46%	NCDR	2010	
	7	Patients (from #1) who are Income Deprived (2)		29%			16%	7%		34%	NCDR	2010	
	8	Male patients (from #1)	161	53%	47%	58%	55%	43%		72%	NCDR	2010	
	9	Number and proportion of patients (from #2) with a stage assigned	326	99%	97%	100%	92%	36%		100%	NLCA	2011	
	10	Number and proportion of patients, excluding SCLC, with stage I or II assigned	83	29%	24%	35%	24%	10%		68%	NLCA	2011	
	11	Number a									NLCA	2011	
	12	Number a									NLCA	2011	
	13	Proportion									NLCA	2011	
Specialist Team	14	Peer review									NCPR	2010/11	
	15	Peer review									NCPR	2010/11	
	16	Peer review									NCPR	2010/11	
	17	Peer review									NCPR	2010/11	
	18	Number a									NLCA	2011	
Throughput and pathology	19	Number c									CWT	2010/11	
	20	Number a									NLCA	2011	
	21	Number a									NLCA	2011	
	22	Number a									NLCA	2011	
	23	Number a									NLCA	2011	
Waiting times	24	Estimated									HES	2011	
	25	Q2 2012/									CWT	2012/13 Q2	
	26	Q2 2012/									CWT	2012/13 Q2	
	27	Urgent GI									CWT	2011/12	
	28	Cases tre									CWT	2011/12	
Practice	29	Q2 2012/									CWT	2012/13 Q2	
	30	No. and p									NLCA	2011	
	31	No. and p									NLCA	2011	
	32	No. and p									NLCA	2011	
	33	No. and p									NLCA	2011	
Outcomes and Recovery	34	No. and p									NLCA	2011	
	35	No. and p									NLCA	2011	
	36	First outp									PBR SUS	2011/12	
	37	NLCA: Median survival in days and adjusted hazard ratio for mortality	170	0.99	0.64	1.11	1.0	0.57		1.49	NLCA	2011	
	38	NLCA: Proportion of patients surviving at one year and adjusted odds ratio of surviving 1 year	34%	1.43	0.97	2.11	1.0	0.40		2.67	NLCA	2011	
Patient Experience - CPES (8)	39	Patients surveyed & % reporting always being treated with respect & dignity (6)	13	n/a			83%	66%		100%	CPES	2011/12	
	40	Number of survey questions and % of those questions scoring red and green (7)	% Red	0	n/a			0%			78%	CPES	2011/12
	% Green		n/a			0%		69%	CPES	2011/12			

- Assess and benchmark a wide range of information at organisation level
- Allows a ‘at glance’ assessment of an organisation

- Assess and benchmark a wide range of information at organisation level
- Allows a 'at glance' assessment of an organisation

Sources of information

- HES data
- Peer Review data
- PAS systems
- Registration
- Cancer Waits
- Audit - where available

Profile anatomy

			Percentage or rate				Trust rate or percentage compared to England					
Section	#	Indicator	No. of patients/ cases or value	Trust	Lower 95% confidence limit	Upper 95% confidence limit	England	Low- est	Range	Highest	Source	Period
Size	1	Number of newly diagnosed lung cancer patients per year, 2010 [experimental] (1)	304				20	41		588	NCDR	2010
	2	Number of NLCA patients - lung cancer	329				19	1		585	NLCA	2011
	3	Number of NLCA patients - mesothelioma	11				1	0		31	NLCA	2011
Demographics (based on newly diagnosed patients, 2010)	4	Patients (from #1) aged 70+	188	62%	56%	67%	61%	39%		75%	NCDR	2010
	5	Patients (from #1) with recorded ethnicity	295	97%	94%	98%	93%	66%		100%	NCDR	2010
	6	Patients (from #5) with recorded ethnicity which is not White-British	3	1%	0%	3%	7%	0%		46%	NCDR	2010
	7	Patients (from #1) who are Income Deprived (2)		29%			16%	7%		34%	NCDR	2010
	8	Male patients (from #1)	161	53%	47%	58%	55%	43%		72%	NCDR	2010
	9	Number and proportion of patients (from #2) with a stage assigned	326	99%	97%	100%	92%	36%		100%	NLCA	2011
	10	Number and proportion of patients, excluding SCLC, with stage I or II assigned	83	29%	24%	35%	24%	10%		68%	NLCA	2011
	11	Number and proportion of patients, excluding SCLC, with a stage IIIA assigned	36	13%	9%	17%	14%	4%		30%	NLCA	2011
	12	Number and proportion of patients, excluding SCLC, with a stage IIIB and IV assigned	167	58%	53%	64%	62%	13%		80%	NLCA	2011
	13	Proportion of patients (from #2) with a Performance Status assigned	286	87%	83%	90%	89%	2%		100%	NLCA	2011
Specialist Team	14	Peer review: Doe									NCPR	2010/11
	15	Peer review: Proj										
	16	Peer review: are										
Throughput and pathology	17	Peer review: are										
	18	Number and prop										
	19	Number of urgent										
	20	Number and proportion of patients (from #2) with confirmed SCLC										
	21	Number and proportion of patients (from #2) with confirmed SCLC										
Waiting times	22	Number and proportion of patients (from #2) with confirmed NSCLC who are diagnosed NOS										
	23	Number and proportion of patients (from #2) with histological confirmation of diagnosis	228	69%	64%	74%	77%	52%		79%	NLCA	2011
	24	Estimated proportion of tumours with emergency presentations [experimental]	94	47%	40%	54%	37%	2%		100%	NLCA	2011
	25	Q2 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks	135	96%	92%	98%	97%	88%		97%	HS	2011
	26	Q2 2012/13: Treatment within 62 days of urgent GP referral for suspected cancer	135	77%	72%	82%	80%	0%		100%	CWT	2012/13 Q2
Practice	27	Urgent GP referrals for suspected cancer diagnosed with cancer [experimental]	135	25%	19%	33%	24%	4%		46%	CWT	2011/12
	28	Cases treated that are urgent GP referrals with suspected cancer [experimental]	34	25%	19%	33%	39%	0%		76%	CWT	2011/12
	29	Q2 2012/13: First treatment began within 31 days of decision to treat	14	100%	78%	100%	99%	91%		100%	CWT	2012/13 Q2
	30	No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy	174	53%	41%	58%	60%	36%		100%	NLCA	2011
	31	No. and proportion resected of patients (from #2) excluding confirmed SCLC	50	17%	13%	22%	16%	0%		38%	NLCA	2011
Outcomes and Recovery	32	No. and proportion resected of patients (from #2) with confirmed NSCLC	48	26%	20%	33%	21%	0%		45%	NLCA	2011
	33	No. and proportion resected of patients (from #2), excluding confirmed SCLC, with stage I and II disease	40	48%	38%	59%	53%	0%		100%	NLCA	2011
	34	No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy	27	68%	52%	80%	68%	0%		100%	NLCA	2011
	35	No. and prop. of patients (from #2) with stage IIIB/IV, PS 0-1 excl. conf. SCLC, receiving chemotherapy	28	58%	44%	71%	55%	0%		100%	NLCA	2011
	36	First outpatient appointments and proportion of all outpatient appointments	23,053	41%	41%	41%	32%	15%		68%	PBR SUS	2011/12
Patient Experience - CPES (8)	37	NLCA: Median survival in days and adjusted hazard ratio for mortality	176	0.95	0.82	1.11	1.1	0.57		1.49	NLCA	2011
	38	NLCA: Proportion of patients surviving at one year and adjusted odds ratio of surviving 1 year	34%	1.43	0.97	2.11	1.1	0.40		2.67	NLCA	2011
	39	Patients surveyed & % reporting always being treated with respect & dignity (6)	13	n/a			83%	66%		100%	CPES	2011/12
	40	Number of survey questions and % of those questions scoring red and green (7)	0	n/a				0%		78%	CPES	2011/12
	41			n/a				0%		69%	CPES	2011/12

Indicator
description
ns

Numbers,
rates,
and comparat
ors

Spine
chart &
range of
data

Source
&
Dates

Profile anatomy

Section	#	Indicator	No. of patients/ cases or value	Percentage or rate			Trust rate or percentage compared to England			Source	Period
				Trust	Lower 95% confidence limit	Upper 95% confidence limit	England	Low- est	Range		
Size	1	Number of newly diagnosed lung cancer patients per year, 2010							588	NCDR	2010
	2	Number of NLCA patients - lung cancer							585	NLCA	2011
	3	Number of NLCA patients - mesothelioma							31	NLCA	2011
Demographics (based on newly diagnosed patients, 2010)	4	Patients (from #1) aged 70+							75%	NCDR	2010
	5	Patients (from #1) with recorded ethnicity	295	97%	94%	98%	93%	66%	100%	NCDR	2010
	6	Patients (from #5) with recorded ethnicity which is not White-British						0%	46%	NCDR	2010
	7	Patients (from #1) who are Income Deprived (2)						7%	34%	NCDR	2010
	8	Male patients (from #1)						43%	72%	NCDR	2010
	9	Number and proportion of patients (from #2) with a stage assigned						36%	100%	NLCA	2011
	10	Number and proportion of patients, excluding SCLC, with stage I or II assigned						10%	68%	NLCA	2011
	11	Number and proportion of patients, excluding SCLC, with a stage IIIA assigned						4%	30%	NLCA	2011
	12	Number and proportion of patients, excluding SCLC, with a stage IIIB and IV assigned						62%	80%	NLCA	2011
	13	Proportion of patients (from #2) with a Performance Status assigned		87%	83%	90%	80%	2%	100%	NLCA	2011
	14	Peer review: Does the specialist team have full membership? (3)								NCPR	2010/11
Specialist Team	15	Peer review: Are there concerns about the specialist team? (3)								NCPR	2010/11
	16	Peer review: Are there concerns about the specialist team? (3)								NCPR	2010/11
	17	Peer review: Are there concerns about the specialist team? (3)								NCPR	2010/11
	18	Number and proportion of patients (from #2) seen by CNS (5)	295	67%	53%	68%	70%	0%	100%	NLCA	2011
Throughput and pathology	19	Number of urgent GP referrals for suspected cancer							853	CWT	2010/11
	20	Number and proportion of patients with a confirmed diagnosis							93%	NLCA	2011
	21	Number and proportion of patients with a confirmed diagnosis							100%	NLCA	2011
	22	Number and proportion of patients with a confirmed diagnosis							79%	NLCA	2011
	23	Number and proportion of patients with a confirmed diagnosis							100%	NLCA	2011
	24	Estimated proportion of tumours with emergency presentations [experimental]	94	47%	40%	54%	37%	2%	97%	HES	2011
Waiting times	25	Q2 2012/13: Urgent GP referral to suspected cancer service within 2 weeks	135	98%	92%	98%	97%	88%	100%	CWT	2012/13 Q2
	26	Q2 20								CWT	2012/13 Q2
	27	Urgent								CWT	2011/12
	28	Cases								CWT	2011/12
	29	Q2 2012/13: First treatment began within 30 days of decision to treat	14	100%	100%	100%	99%	91%	100%	CWT	2012/13 Q2
Practice	30	No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy	174	53%	47%	58%	60%	36%	100%	NLCA	2011
	31	No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy						16%	38%	NLCA	2011
	32	No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy						21%	45%	NLCA	2011
	33	No. and proportion of patients (from #2), excluding confirmed SCLC, with stage I and II assigned						53%	100%	NLCA	2011
	34	No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy						68%	100%	NLCA	2011
	35	No. and proportion of patients (from #2) with stage IIIB/IV, PS 0-1 and confirmed SCLC receiving chemotherapy							100%	NLCA	2011
Outcomes and Recovery	36	First outpatient appointments and proportion of all outpatient appointments							68%	PBR SUS	2011/12
	37	NLCA: Median survival in days and adjusted hazard ratio for mortality							1.49	NLCA	2011
	38	NLCA: Proportion of patients surviving at one year and adjusted hazard ratio for mortality							2.67	NLCA	2011
Patient Experience - CPES (8)	39	Patients surveyed & % reporting always being treated with respect & dignity (6)						33%	66%	CPES	2011/12
	40	Number of survey questions and % of those questions scoring red and green (7)						0%	78%	CPES	2011/12
	41							0%	60%	CPES	2011/12

Size – no. patients

diagnosed Patient

demographics

Specialist team – Peer Review concerns and stage (1/3)

Throughput and pathology – patient

Waiting times performance and

Conversion/deter Clinical

Outcomes and

re Patient

Next steps

Update existing profiles (March 2015)

New platform – Fingertips?

Align clinical indicators with CHI's

<https://www.cancertoolkit.co.uk/>

Nicky.coombes@phe.gov.uk

020 7654 8148

Aim: Benchmark and assess trust/MDT for commissioning & clinical review

Published September 2013 (developed from similar Breast/Colorectal/Lung profiles published Dec 2011, Feb 2013)

A NCIN / London KIT co-production in partnership with NCPR and NOGCA

Hosted in the Cancer Commissioning Toolkit

Headings are set in 40 pt Arial

Large body copy should be set in 18pt Roman, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exerci tation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat.

Large subheadings set in 18pt Arial

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exerci tation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat.

